Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions

SAN MATEO, Calif., February 07, 2008 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that data from the Phase II trial of its novel secretory phospholipaseA2 inhibitor Varespladib (A-002) for the treatment of coronary heart disease will be presented as a late breaker at the 2008 of Cardiology 57th Annual Scientific Session on Monday, March 31, 2008 in Chicago, Illinois.

The Phase II trial known as PLASMA (Phospholipase Levels And Serological Markers of Atherosclerosis) was a multi-center, randomized, double-blind, placebo-controlled trial that enrolled approximately 400 patients with stable coronary heart disease in the U.S. and Ukraine. Subjects were randomized to receive one of four different doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint was a reduction in secretory phospholipase A2 (sPLA2). The study also evaluated the effect of Varespladib on cholesterol levels (LDL-C, non-HDL and total cholesterol) as well as inflammation in patients with stable coronary heart disease.

    PLASMA Late-Breaker Trial Data Presentation:


    Date/Time: Monday, March 31 from 2:30-2:45pm.


    Title/Author:  Effects of a Selective Inhibitor of Secretory

    Phospholipase A2 on Low Density Lipoproteins and Inflammatory Pathways,

    Robert S. Rosenson, MD, Director, Lipoprotein Disorders and Clinical

    Atherosclerosis Research, Division of Cardiovascular Medicine at the

    University of Michigan, for the PLASMA Investigators.


    Location:  McCormick Place, Vista Room S406

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co.Â? Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienesÂ? prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novelÂ? upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com.

MEDIA CONTACT:

Anne Bowdidge (650) 218-6900

pr@anthera.com

CONTACT: Anne Bowdidge, +1-650-218-6900, , for AntheraPharmaceuticals, Inc. pr@anthera.com

Web site: http://www.anthera.com/

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: February 2008

View comments

Hide
(web5)